| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has 2 insiders with recent SEC Form 4 filings, including 13 buys and 0 sells. COAG is classified in the Biotechnology industry within the Healthcare sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 6.44M | $188.44M | +67.7K | |
| Other | 49.0K | $1.43M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Ra Capital Management, L.P.53 | 10% Owner | Buy | 67,669 | $24.97 | $1,689,818.48 | +0.5% | |
| May 11, 2026 | Ra Capital Management, L.P.53 | 10% Owner | Buy | 51,258 | $24.75 | $1,268,594.26 | +0.2% | |
| May 6, 2026 | Ra Capital Management, L.P.53 | Director, 10% Owner | Buy | 2,840,429 | $18.39 | $52,222,945.65 | +9.9% |